TRANSCENTA-B News

TRANSCENTA-B (06628) announced at AACR 2025 a new type of antibody-drug conjugate (ADC) targeting FGFR2b, conjugated with a topoisomerase I inhibitor, showing encouraging anti-tumor activity in preclinical tumor models.

TRANSCENTA-B (06628) announced that the company will participate in the 2025 American Association for Cancer Research Annual Meeting (AAC...)

Zhitong FinanceApr 29 18:17 ET

Would Transcenta Holding (HKG:6628) Be Better Off With Less Debt?

Simply Wall StApr 29 02:20 ET

TRANSCENTA-B: 2024 ANNUAL REPORT

HKEXApr 22 04:37 ET · Announcements

TRANSCENTA-B (06628.HK) awarded 0.676 million shares as stock incentives.

Gelonghui, April 2nd丨TRANSCENTA-B (06628.HK) announced that the Board of Directors decided to grant 0.676 million shares of reward stock to 27 award recipients according to the stock incentive plan on April 2, 2025.

Gelonghui FinanceApr 2 05:58 ET

TRANSCENTA-B: SUPPLEMENTAL ANNOUNCEMENT

HKEXMar 30 19:20 ET · Announcements

Express News | Transcenta Holding Limited FY Revenue RMB 11.3 Million

ReutersMar 30 06:21 ET

TRANSCENTA-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024;AND CHANGE IN USE OF PROCEEDS

HKEXMar 30 06:20 ET · Announcements

TRANSCENTA-B (06628.HK) plans to hold a Board of Directors meeting on March 28 to approve annual performance.

Gelonghui March 14th丨TRANSCENTA-B (06628.HK) announced that the Board of Directors has scheduled a meeting on March 28, 2025, to consider and approve the annual performance of the group for the year ending December 31, 2024, and the proposed final dividend (if any), as well as to address Other matters.

Gelonghui FinanceMar 14 04:59 ET

TRANSCENTA-B: DATE OF BOARD MEETING

HKEXMar 14 04:39 ET · Announcements

[Brokerage Focus] Softbank China gives a strong Buy rating to Chuangsheng Group (06628), indicating that its potential value is underestimated by the market.

Jinwu Financial News | Softbank China Research indicates that Chuangsheng Group (06628) has an experienced and comprehensive team, with Global clinical research and development capabilities in China and the USA. They employ a multi-regional development Global Strategy, utilizing proprietary antibody discovery platforms, integrated CMC capabilities, advanced translational science platforms, and HiCB manufacturing technology to advance innovations in drugs for various diseases, while also providing CDMO services to generate revenue. The company's core product Osemitamab (TST001) is a potentially best-in-class humanized antibody targeting Claudin18.2 (CLDN18.2).

Jinwu Financial NewsFeb 24 00:49 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

On January 14, TRANSCENTA-B (06628) spent 0.0244 million Hong Kong dollars to repurchase 0.0405 million shares.

TRANSCENTA-B (06628) announced that on January 14, 2025, the company invested 0.0244 million Hong Kong dollars...

Zhitong FinanceJan 14 06:07 ET

TRANSCENTA-B (06628.HK) repurchased 0.01 million shares on January 10.

Gelonghui January 10th丨TRANSCENTA-B (06628.HK) announced that on January 10th, it spent HKD 6,100 to repurchase 0.01 million shares.

Gelonghui FinanceJan 10 06:26 ET

TRANSCENTA-B (06628.HK) spent 0.06 million HKD to repurchase 0.1 million shares on January 9.

On January 9, Legend Holdings Group-B (06628.HK) announced that it spent 0.06 million Hong Kong dollars to repurchase 0.1 million shares.

Gelonghui FinanceJan 9 05:49 ET

TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.

Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.

Gelonghui FinanceJan 3 05:33 ET

TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares on December 31.

Gelonghui, on December 31, announced that TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares, with a repurchase price ranging from 0.59 to 0.63 HKD per share.

Gelonghui FinanceDec 31, 2024 02:53 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 04:16 ET

TRANSCENTA-B (06628) announced the latest Business progress on its new LIV-1 ADCs for the antitumor effects in models of triple-negative breast cancer at the 2024 SABCS.

TRANSCENTA-B (06628) announced that the 2024 San Antonio Breast Cancer Symposium (SABCS)...

Zhitong FinanceDec 12, 2024 17:36 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8, 2024 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8, 2024 03:48 ET